Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.